Editorial

BPC-157 just got a federal advisory committee's recommendation, months after coming off a safety watchlist. Here's what actually happened in between, and what the recommendation does and doesn't mean for the vial in your fridge.

BPC-157's animal and anecdotal record for tendon and gut repair is unusually consistent. Whether that holds up in a human body is a question no completed trial has answered yet.

BPC-157's rat data has held up for decades. Whether that mechanism does anything for the actual human joint you're injecting it into is a question a brand-new Phase 2 trial has only just started to answer.

The oral-versus-injectable debate for BPC-157 gets argued with total confidence online. The actual bioavailability data behind those arguments, in either direction, is worth checking before you pick a side.

PCAC voted to recommend BPC-157 and TB-500 for the FDA's 503A compounding list, each on its own 8-6 vote. Here's what the human trial record for each peptide shows, and where the case for stacking them turns from evidence into theory.

BPC-157, TB-500, and GHK-Cu are sold as one interchangeable injury-recovery stack, but their human evidence ranges from a real Phase 2 trial to a molecular identity gap to a null placebo-controlled result. Each is graded on its own record, not the group's pitch.

Thymosin Alpha-1 is a real, internationally approved drug for a documented immune deficit, not a peptide-store rumour. Whether that same signal holds for a healthy 50-year-old with no diagnosis is the part nobody has actually tested.

Semax has a documented mechanism and a quarter-century of authorised use in Russia. Whether either of those things adds up to evidence a Western reader can actually check is a separate, unresolved question.

AOD-9604 isolates the fat-burning piece of growth hormone from the piece that makes you grow. Whether that clean design actually worked in a human body, and what regulators decided about it, is the open question here.

One Soviet-era mouse study says a four-amino-acid peptide can lengthen the cap on your DNA. Twenty-five years later, nobody outside that lab has checked whether it's real, or whether it means anything for how long you live.

GHK-Cu drops sharply with age and does striking things to cells in a dish. Whether any of that survives contact with actual human skin is a separate, unresolved question.

GHK-Cu has some of the cleanest cell-biology data in peptide science: gene remodelling, wound signalling, antioxidant activity. Whether any of that survives the jump from a dish to a human body is still an open question.

Every study on GHK-Cu's wound-healing chemistry stops at the fibroblast dish. What happens once a wound closes, in the weeks that actually build a scar, is a different, mostly untested question.

GHK-Cu has a plausible, multi-pathway mechanism for hair-follicle regeneration, but almost all the evidence is in vitro and animal-model work from the 1990s and 2000s. No human trial has tested it in hair, and the sole human RCT in skin found no effect.

Thymosin beta-4's actin-grabbing mechanism is well mapped in the lab. Whether an injected synthetic version actually speeds tendon repair in a human body is a question the published research has never actually asked.

TB-500's reputation rides on real experiments with thymosin beta-4 in animals. Whether that evidence covers the molecule people are actually injecting is a separate, open question.

TB-500 gets sold as an anti-inflammatory peptide. The animal studies behind that claim used a different molecule than the one in most vials, and nobody has tested whether timing during the wound's inflammatory window changes the outcome.

TB-500's reputation rests on tendon anecdote, but the peer-reviewed record on thymosin beta-4 is overwhelmingly cardiac: actin sequestration, epicardial progenitor signaling, coronary angiogenesis. No human cardiac trial exists, and grey-market TB-500 may not match the molecule studied.

PCAC decided something about BPC-157 in July 2026, and most of the peptide world still can't say what, or what it doesn't mean.

KPV's rodent gut and inflammation data is genuinely coherent. Whether any of that biology survives contact with a human body has never been tested.

KPV's gut and immune-cell science is solid. Whether that translates into a working skin-barrier product is the open question nobody's tested yet.

KPV, a three-amino-acid fragment of alpha-MSH, shows a consistent anti-inflammatory signal in cells and mice. No human trial has tested whether that mechanism, or its proposed MC1R selectivity, works the same way in a person.

KPV, a three-amino-acid fragment of alpha-MSH, quiets inflammatory signalling in cell studies and a single mouse colitis trial. Whether it reaches inflamed human gut tissue, and works there, has never been tested.

The Wolverine Stack pairs BPC-157 and TB-500 into one repair protocol — on paper a genuinely good idea: two peptides doing two different repair jobs. Here's what the pairing is meant to do for you, why the biology is exciting, and the one thing nobody has ever tested — the two of them run together.

Everyone heard "peptides are coming back." Almost nobody heard that the FDA already sat down with some of the most-stacked ones and voted no. Here's which, when, and what a July 2026 yes would actually buy you.

BPC-157 is the repair peptide half the gym is talking about. Strip out the forum noise and the answer is simple: in animals it speeds healing by growing new blood supply into injured tissue. Here is what that could mean for you, how far the human proof goes, and what the FDA is about to review.

GHK-Cu is a copper-carrying peptide your body makes to repair itself, and makes less of as you age. Here's the plain-English answer: what it could do for you, why the biology is exciting, how far the human proof goes — and where the injectable form sits in the FDA's next compounding review.

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

Two days at FDA's White Oak campus decided which of seven peptides US compounding pharmacies may eventually dispense by prescription. The recommendation is not an approval, the docket is not all the peptides, and the framing the forums used going in was mostly wrong.

Chronic, low-grade inflammation tracks with slower recovery, stiff joints, and how fast you age. Three peptides under FDA review — KPV, BPC-157, and GHK-Cu — each turn it down from a different direction. Here is what that could mean for you, and how far the human proof actually goes.

Most fat-loss peptides work by turning up your whole growth-hormone system and hoping the fat follows. AOD-9604 skips that and talks to the fat cell directly — a cleaner idea. Here is how the mechanism works, why your fat is a hormone-producing organ, and how far the human proof actually goes.

The thymus trained every immune cell you own, then started shrinking in your teens. Its slow fade is a big reason immunity gets weaker with age — and the reason a family of thymus-signal peptides is worth understanding. Here is the biology, in plain language.

You don't need a biology degree to judge peptide evidence yourself. You need five questions. Ask them of any study a seller quotes at you and the real signal pulls away from the sell — and the whole field gets more exciting once you can tell which promises have something under them.

Collagen is the scaffolding under your skin, tendons, and joints — and three peptides now in front of the FDA each lean on how your body builds it. Here is what that could mean for repair and ageing, why the biology is genuinely exciting, and how far the human proof actually goes.

Most peptides come as a vial and a needle for one reason — swallow them and your gut destroys them before they can work. Understanding how a peptide actually gets into your body is the single lens that tells you whether a product can work at all. Here is how it works, in plain English.

Your body has a switch for stress — it should flip on under load and off when it passes. When it stops flipping off, you get the wired-and-foggy version most men know. Here is how that switch works, and how two Russian peptides could help it behave.

Copper is a metal your body repairs itself with — but too reactive to carry loose, so it travels clipped to a small peptide. That's a copper peptide, like GHK-Cu. Here's why the biology is exciting, how far the human proof goes, and where the injectable sits in the FDA's next compounding review.

Telomeres cap your chromosomes, and get shorter every time a cell divides. Reset that countdown and you'd slow ageing itself — the longevity holy grail. Here's the real biology, what could move it, and why telomere-lengthening as anti-ageing is still unproven in humans.

Repair runs on fresh plumbing — new blood vessels growing into damaged tissue. It's the mechanism three of the most-talked-about recovery peptides — BPC-157, TB-500 and GHK-Cu — are built on. Here's what that could mean for how you heal, and the one question the same biology always raises.

CJC-1295, ipamorelin, sermorelin, and tesamorelin share one job — getting your own pituitary to release more growth hormone, the repair-and-recovery signal that fades after your twenties. Here is the appeal, the two peptide families inside the class, and how far the human proof actually goes.

MOTs-C and Epitalon are two very different longevity bets — one on your metabolism, one on the clock inside your cells. Here is what each could do for you, which angle fits your goal, and how far the human proof goes on both.

Your mitochondria don't just make energy — they send hormone-like signals that tell the body how to run, and the supply fades with age. Mitochondrial-derived peptides are that family. Here's what the class could do, how far proof goes, and where its most-studied member sits in July's FDA review.

BPC-157's reputation rests on one mechanism — it appears to build fresh blood supply into damaged tissue. Here is that mechanism in plain language, angiogenesis and nitric oxide made simple, what it could mean for recovery, how far the animal proof goes, and the FDA review set for July 2026.

Peptides are the short chains of amino acids your body already uses to send signals — repair this, burn that, grow here. Some are drugs you trust, like insulin. Others are early and genuinely exciting. Here is the plain map of what they are, what they might do for you, and where the science stands.

BPC-157 and GHK-Cu both get sold as tissue-repair peptides, but they are tools for two different jobs — BPC-157 for deep tissue like tendon and gut, GHK-Cu for skin and surface. Here is what each could do for you, which goal each one fits, and how far the proof actually goes.

Sermorelin and tesamorelin both nudge your pituitary to make more growth hormone. One targets deep visceral fat with a real Phase 3 behind it; the other is the gentler GH-axis nudge with an FDA past. Here's which one fits which goal — and why one is still an approved drug and the other isn't.

CJC-1295 and ipamorelin are the internet's favourite growth-hormone pairing — but they do two different jobs. One raises your GH baseline for days from a single shot; the other fires a clean nightly pulse. Here's what each could do for you, which fits which goal, and why so many people run both.

BPC-157 and TB-500 aren't two flavours of one recovery peptide — they're unrelated proteins aimed at different kinds of damage. Here is what each could actually do for you, which one fits which injury, and how far the human proof goes for both.

Selank is Russia's attempt at an anxiety peptide that takes the edge off without the sedation, the fog, or the dependence a benzodiazepine leaves you with. The early promise is real and genuinely interesting — here's what it could do for you, and how far the human proof actually goes.

Ipamorelin asks your own body to release a clean pulse of growth hormone — the recovery, sleep and body-composition signal — without the stress-hormone mess older compounds caused. Here's what that could mean for you, and how far the human proof actually goes.

CJC-1295 is engineered to make your own pituitary release growth hormone for days from a single shot — and unusually, a real human trial says it works. Here's what that could mean for recovery, sleep and body composition, how far the proof goes, and why one name hides two different compounds.

Sermorelin is the growth-hormone peptide with a real FDA past — and a clever way of working: it nudges your own gland to make more GH instead of overriding it. Here's what it could do for you, how far the human proof actually goes, and why its availability isn't waiting on the July FDA vote.

MOTS-c is a tiny peptide your mitochondria release when you train — a signal that tells your body to handle fuel and hold onto strength like a younger one. The early science is genuinely exciting. Here is what it could do for you, and how far the human proof actually goes.

Selank and Semax get sold side by side as brain peptides, but they solve opposite problems — one calms, one sharpens. Here's what each could do for you, how far the Russian evidence actually goes, and why the July 2026 FDA review splits them apart.

DSIP (Emideltide on the FDA paperwork) is a peptide your body makes that peaks in your deepest sleep. The idea — hand it back to push deeper sleep and a steadier stress system — is genuinely interesting. Here is what it could do for you, and why the best human trial came back cold.

Epithalon is the shortest peptide on the longevity menu, built on one bold idea — switching telomerase back on to rebuild the caps on your chromosomes. Here is what it could do for you, how far the proof actually goes, and where it sits on the July 2026 PCAC docket.

You've probably met ipamorelin as the second half of CJC-1295 and ipamorelin. On its own it's the quieter half — a small peptide built to ask your own body for a clean pulse of growth hormone. Here's what it could mean for you, why it earned the clean name, and how far the human proof goes.

MOTS-c is a tiny peptide your mitochondria make to help the body handle fuel and hold onto strength — and the level falls with age. Here's the plain-English tour: what it is, what the early science says it might do, and where the July 2026 FDA review just put it.

PT-141 (bremelanotide) does something the familiar blood-flow pills can't — it works on desire itself, up in the brain. And it is the rare peptide carrying a real FDA approval and Phase 3 evidence behind it. Here is what it could do for you, and exactly how far that proof actually reaches.

Selank is a small peptide Russia has used for anxiety since 2009 — calm without the benzodiazepine baggage, built from a fragment your immune system already makes. Here is what it is, what it might do, how good the evidence really is, and where it stands with US regulators.

Semax is a Russian brain peptide with an unusual credential — three decades of real clinical use in stroke care, not just a biohacker rumour. Here is what it could do across neuroprotection and focus, how far the proof runs, and its spot on the FDA's July 2026 PCAC docket.

Sermorelin is the rare longevity peptide with an actual FDA past: sold as Geref, first as a diagnostic and then as a treatment for kids who couldn't make enough growth hormone. Here's what it is, what the human evidence covers, and where it sits with the FDA and WADA now.

Tesamorelin is the rare peptide that went through a Phase 3 trial and came out an approved drug — and what it targets is the deep, dangerous belly fat. Here is what it could do for you, and exactly where the approved evidence stops and off-label hope begins.

Thymosin Alpha-1 is the rare peptide that is already an approved drug in dozens of countries — a signal your thymus makes to run your immune system, and makes less of as you age. Here is what it could do for you, the range of what it has been used for, and where the US regulation actually stands.

CJC-1295 reliably raises GH and IGF-1 in humans, confirmed by a single 2006 pharmacokinetic study. Whether that translates into any functional benefit has never been tested.